Analysis of the Efficacy of Rituximab in Microlesional Nephropathy
Objective To explore the efficacy of rituximab in microlesional nephropathy.Methods Sixty cases of mi-croscopic lesion nephropathy patients admitted to Zhejiang Provincial People's Hospital from January 2022 to Decem-ber 2023 were non-randomly selected and divided into two groups according to treatment methods.Thirty cases in the control group were treated with hormone sequestration therapy,and thirty cases in the observation group were treated with rituximab combined with hormone sequestration therapy.Compared the treatment effect,biochemical indexes,in-cidence of adverse reactions and recurrence rate of the two groups.Results The therapeutic effect of the observation group was better than that of the control group,and the difference was statistically significant(P<0.05).The level of biochemical indexes of the observation group were better than those of the control group,and the differences were sta-tistically significant(all P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).The recurrence rate of the observation group was 7.14% (2/28),which was lower than 34.78% (8/23)in the control group,and the difference was statistically significant(χ2=4.492,P=0.034).Conclu-sion Rituximab treatment for microscopic lesion nephropathy improves treatment efficacy and clinical symptoms with a favorable safety profile and reduced relapse rate.
NETL
NSTL
万方数据
